PNH Today

It is our mission to enhance scientific knowledge on paroxysmal nocturnal hemoglobinuria (PNH) in the effort to improve patient care.

[PNH Today @PNHToday]

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery https://t.co/208lDHFlyT

[PNH Today @PNHToday]

New review on mechanisms of complement system, its role in clinical conditions & promising therapeutic approaches: https://t.co/3Zrz2xghN3

[PNH Today @PNHToday]

Upcoming webinar on 11/5: "Advanced Understanding of PNH in 2015: Hemolytic Anemia, Pancytopenia, and Thrombosis" | https://t.co/d67JmXU1MW

[PNH Today @PNHToday]

In the December issue for the Journal of Clinical Immunology: "Applying complement therapeutics to rare diseases" | http://t.co/dPy3ZAtiE9

[PNH Today @PNHToday]

.@aamdsif is endorsing the clinical development of Amyndas Pharmaceuticals’ AMY-101 as a novel treatment for PNH: http://t.co/KiEubYV9ue

[PNH Today @PNHToday]

Upcoming webinar on "MDS, Aplastic Anemia and PNH in 2015: What We Know About Who Gets Them and Why?" To learn more: http://t.co/E2EkrhhkjO

[PNH Today @PNHToday]

In this month's Blood (http://t.co/JqLK4ExFSG): "Complement C3dg-mediated erythrophagocytosis: Implications for PNH" http://t.co/2xJoY5sEeX

[PNH Today @PNHToday]

The "Walk for PNH" (the nation's largest fundraising event for PNH) is scheduled for September 20, 2015: http://t.co/bhT6mz6aRv